Previous studies have shown that both plasma exchange (PE) and double filtration plasmapheresis (DFPP) are effective treatments in Guillain-Barré syndrome (GBS). Whether PE and DFPP have similar effects in GBS is not clear. This report compares the therapeutic effectiveness of PE and DFPP in GBS patients treated in 3 major hospitals in northern Taiwan. A total of 102 patients were included in this survey, including 39 with PE (hereafter PE group) and 63 with DFPP (hereafter DFPP group). Both groups showed significant improvement of disability scores after treatment. However, time to onset of effect was shorter (5.6 ± 3.5 versus 7 ± 3.4 days, p < 0.05), and changes of disability scores were more prominent (1.3 ± 0.8 versus 0.8 ± 0.8, p < 0.05) in the PE group than the DFPP group. Mortality and outcome after 6 months were not different between the 2 groups. In conclusion, both PE and DFPP are effective treatments in GBS. PE was superior to DFPP in short-term effectiveness. The long-term effectiveness was not different.
Guillain-Barré syndrome (GBS) is an immunemediated, inflammatory disease of the peripheral nervous system (1) . The clinical features consist of acute or subacute onset of weakness with areflexia and sensory deficits (2) . Several clinical studies have shown appreciable short-term benefits from plasma exchange (PE) in GBS patients (3) (4) (5) (6) . In addition, a long-term beneficial effect from PE also was seen in 1 study (7) . Therefore, PE as a standard treatment in GBS has been accepted widely.
Procedures of PE comprise removal of plasma from whole blood during extracorporeal perfusion and replacement with normal plasma or suitable colloid (8, 9) . The potential adverse effects of this treatment include allergic reaction, infection, and hypotension (9, 10) . Double filtration plasmapheresis (DFPP) is a newly developed apheretic technique. This procedure consists of separation of plasma from whole blood through a plasma separator and then removal of components of plasma through a plasma fractionator. The treated plasma is then mixed with cellular blood components and reinfused back into the patient's circulation without the need for replacement fluid. Therefore, DFPP is theoretically free of the risk of transfusion-transmitted infections.
Recent studies have shown that DFPP is effective in the treatment of various autoimmune-mediated neuromuscular diseases including GBS and myasthenia gravis (11, 12) . Whether PE and DFPP have similar effects in GBS is not clear. This report compares the effectiveness of PE and DFPP in GBS patients treated in 3 major hospitals in northern Taiwan.
PATIENTS AND METHODS
We reviewed the medical records of all patients who received PE or DFPP in the LinKou Medical Center of the Chang Gung Memorial Hospital (LKCGMH), Shin-Kong WHS Memorial Hospital (SKMH), and the National Taiwan University Hospital (NTUH) between January 1987 and June 2000. Only those who fulfilled the diagnostic criteria for GBS (13) were included for analysis. We recorded data on age, sex, prodromal events, date of onset of disease, clinical manifestations including initial symptoms and neurological findings during the course, as well as date, methods, and complications of PE and DFPP. All patients were graded using a disability score modified from Hughes et al. (14) . Grade 0 is defined by normal functional state without neurological deficits, Grade 1 by minor symptoms or signs but being able to do manual work, Grades 2 and 3 by ambulation without or with assistance, respectively, Grade 4 as being chair or bed bound, Grade 5 as requiring a mechanical ventilator, and Grade 6 as death.
In the LKCGMH, both PE and DFPP were employed in the treatment of patients. In the SKMH, DFPP was the main therapeutic apheresis used whereas in the NTUH only PE was applied clinically. The procedure for 1 course of PE or DFPP was a set of 5 sessions of apheresis over a period of 7 to 12 days. Approximately 3,000 ml of plasma (50 ml/kg body weight) was treated in each session. Equipment, vascular access, and replacement fluid used during PE and DFPP were left to the discretion of the attending physicians at each hospital. The replacement fluid used during PE was either fresh frozen plasma (FFP) or 5% albumin and replacement solution used during DFPP was either 5% albumin or 0.9% normal saline.
The effectiveness of PE and DFPP was assessed according to the muscle strength and disability score before and after a course of apheresis. An effective treatment was defined by improvement of at least 1 Medical Research Council (MRC) score of muscle strength in at least 2 limbs or improvement of 1 disability score within 2 weeks after a complete course of treatment. Outcome was determined according to the functional recovery of the patients 6 months after onset of neuropathy. A good outcome was defined by a satisfactory recovery and resumption of a normal functional life (disability grade of 0 or 1). Poor outcome was defined by persistent disability or death during admission to the hospital (disability grade of 2 or greater). Student's t-test and 2-sided Fisher's exact test were used for comparative analysis.
RESULTS
A total of 102 patients were included in this survey, including 39 with PE (hereafter the PE group) and 63 with DFPP (hereafter the DFPP group). In the PE group, 33 patients received FFP as the replacement solution, and 6 patients received 5% albumin. In the DFPP group, 37 patients received 5% albumin, and 26 patients received 0.9% normal saline. Table 1 summarizes the clinical features and treatment responses of the PE and DFPP groups. The sex distribution, age of onset, percentage of patients with prodromal events, evolving time to nadir, disability scores at nadir before and after a course of apheresis, duration from onset of neuropathy to the time of apheresis, percentage of patients with improvement and complications after therapeutic apheresis, as well as mortality, percentage of patients with good outcome, and outcome scale 6 months after onset were not significantly different between these 2 groups. Both groups showed significant improvement of disability scores (p < 0.001) after a course of apheresis. However, the onset of effectiveness was quicker (5.6 ± 3.5 versus 7 ± 3.4 days, p < 0.05), and the changes of disability scores were more prominent (1.3 ± 0.8 versus 0.8 ± 0.8, p < 0.05) in the PE group than in the DFPP group. Complications of the apheresis were noted in 10 (26%) patients with PE and 8 (13%) with DFPP ( Table 2) . Minor complications such as allergic reaction and transient hypotension were encountered most commonly. In the PE group, all but 1 patient who had apheresis-related complications received FFP as the replacement fluid. Serious complications during PE included hepatitis in 2 patients and sepsis in another 2; all these 4 patients received FFP. One of the 2 patients complicated with sepsis in the PE group had pneumonia. Hence, the source of sepsis in this patient was obviously from the lung. The other patient had no noticeable infectious source. Her blood culture sampled 3 days after removal of the double lumen grew Staphylococcus aureus. Because S. aureus is a common pathogen residing on the skin and the infection occurred within days after the therapeutic apheresis, the sepsis was apparently related to apheresis procedures. The reason for sepsis in this patient was infection of long-term vascular access. Serious complications during DFPP included severe hypotension followed by death in 1 patient, catheter infection in 2, and deep vein thrombosis in another.
One patient (1%) died during the treatment of DFPP in our series. The patient had severe autonomic dysfunction with alternative tachycardia and bradycardia and episodic hypotension in the acute stage of neuropathy. She developed severe hypotension (blood pressure dropped to 50/20 mm Hg) about 30 min after the first session of apheresis on the sixth day after the onset of neuropathy. The next day, her blood pressure was not measurable even under vasopressor therapy. The patient died 2 days later. Therefore, the cause of death in this patient was severe autonomic failure, and the procedure of therapeutic apheresis might have been a precipitating factor of mortality.
DISCUSSION
In this survey, we analyzed the effectiveness of 2 different methods of therapeutic apheresis in treating patients with acute GBS. Two weeks after PE and DFPP therapy, 90% and 78% of GBS patients showed considerable clinical improvement, respectively. The mean disability scores also were improved significantly after the therapeutic apheresis in both patient groups. Therefore, our results show that both PE and DFPP are effective treatments in GBS.
Previous reports that directly compared the therapeutic effectiveness between PE and DFPP are rare. Tagawa et al. showed that PE decreased the immunoglobulin (Ig) G concentration more than DFPP did. The abilities to remove antiganglioside IgG antibodies in PE were markedly superior to those of DFPP (15) . Hence, they recommended that PE should be the first plasmapheresis choice for GBS. Sasaki et al. reported on 2 GBS patients refractory to double filtration plasmapheresis but responsive to PE with FFP (16). In our study, the change in disability scores after therapeutic apheresis was more prominent (1.3 ± 0.8 versus 0.8 ± 0.8, p < 0.05), and time to onset of effect was quicker (5.6 ± 3.5 versus 7.0 ± 3.4 days, p < 0.05) in patients with PE than in those with DFPP. This suggested that short-term effectiveness of apheresis was superior in PE to DFPP. On the other hand, the long-term effect, as measured by percentage of patients with good outcome and outcome scale at 6 months, was not different between these 2 treatments.
The rationale for therapeutic apheresis in the treatment of acute GBS is based on removal of circulating factors causing the autoimmune neuropathy (17) . Why the short-term therapeutic effect of PE is superior to that of DFPP in GBS is unclear. One reason might be that, while PE removes whole plasma nonselectively, DFPP selectively extracts large molecule substances from plasma (16) . Consequently, certain portions of circulating pathologic factors might reside in the plasma after each course of DFPP.
The reason why the short-term effectiveness of PE and DFPP in GBS was different but the long-term effectiveness was comparable between the 2 groups is also unclear. In 3 randomized controlled clinical studies (3-5), a significant short-term beneficial effect of plasmapheresis in GBS was demonstrated in all. However, only 1 of the 3 studies (7) showed longterm benefit from plasmapheresis. Hence, the effectiveness of therapeutic apheresis in GBS is mainly in accelerating the recovery of neuropathy. Therefore, the long-term effectiveness of therapeutic apheresis in GBS might not be different between different procedures.
Complications are not uncommon during plasmapheresis. Minor complications occur in about 20% to 40% of plasmapheresis procedures (9, 10) . These include chills and fever, allergic reaction, nausea, and transient hypotension. More serious complications such as thrombosis or perforation of major vessels, catheter infection (18) , viral hepatitis (10), or even death related to plasmapheresis (19) were occasionally seen. In the majority of patients complicated by viral hepatitis or death, FFP was used as a replacement fluid (10, 19) . Therefore, some authors advised against using it as a replacement fluid (10) .
In our study, apheresis-related complications occurred in about 20% of patients. Most complications were minor adverse events. The incidence of death related to plasmapheresis was 1%. These figures are similar to those in previous studies. In patients who were treated by PE, most complications involved those receiving FFP. Therefore, our results suggest that FFP might not be suitable as a replacement fluid.
CONCLUSIONS
Our results show that both PE and DFPP are effective treatments in GBS. PE was superior to DFPP in short-term effectiveness. The long-term effectiveness was not different between these 2 treatments. Although rare, serious complications did occur during these procedures.
